Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer

References

• JemalASiegelRXuJWardECancer statisticsCA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• ArriagadaRSpielmannMKoscielnySPatterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifenAnn Oncol20021391378138612196363
   PubMed Web of Science ®Google Scholar
• RiveraEManagement of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanesAm J Clin Oncol201033217618519675449
   PubMed Web of Science ®Google Scholar
• FumoleauPDelgadoFMDelozierTPhase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapyJ Clin Oncol1993117124512528315421
   PubMed Web of Science ®Google Scholar
• LivingstonRBEllisGKGralowJRDose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancerJ Clin Oncol1997154139514009193331
   PubMed Web of Science ®Google Scholar
• SmorenburgCHBontenbalMSeynaeveCPhase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxaneBreast Cancer Res Treat2001661838711368414
   PubMed Web of Science ®Google Scholar
• BlacksteinMVogelCLAmbinderRGemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trialOncology20026212811810037
   PubMed Web of Science ®Google Scholar
• ModiSCurrieVESeidmanADA phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxaneClin Breast Cancer200561556015899073
   PubMedGoogle Scholar
• BlumJLJonesSEBuzdarAUMulticenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancerJ Clin Oncol199917248549310080589
   PubMed Web of Science ®Google Scholar
• BlumJLDierasVLo RussoPMMulticenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patientsCancer20019271759176811745247
   PubMed Web of Science ®Google Scholar
• OshaughnessyJABlumJMoiseyenkoVRandomized, open-label, phase II trial of oral capecitabine (Xeloda) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancerAnn Oncol20011291247125411697835
   PubMed Web of Science ®Google Scholar
• LowJAWedamDBLeeJJPhase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancerJ Clin Oncol200523122726273415837987
   PubMed Web of Science ®Google Scholar
• ThomasETaberneroJFornierMPhase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancerJ Clin Oncol200725233399340617606975
   PubMed Web of Science ®Google Scholar
• PerezEALerzoGPivotXEfficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabineJ Clin Oncol200725233407341417606974
   PubMed Web of Science ®Google Scholar
• RocheHYelleLCognettiFPhase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapyJ Clin Oncol200725233415342017606972
   PubMed Web of Science ®Google Scholar
• BatistGHarrisLAzarniaNLeeLWDaza-RamirexPImproved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysisAnticancer Drugs200617558759516702817
   PubMed Web of Science ®Google Scholar
• Al-BatranSEGuntnerMPauligkCAnthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trialsBr J Cancer2010103101518152320978502
   PubMed Web of Science ®Google Scholar
• GradisharWJTjulandinSDavidsonNPhase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerJ Clin Oncol200523317794780316172456
   PubMed Web of Science ®Google Scholar
• CardosoFSenkus-KonefkaEFallowfieldLCostaACastiglioneMESMO Guidelines Working GroupLocally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 5v15v1920555067
   PubMed Web of Science ®Google Scholar
• HoJZhangLTodorovaLWhillansFCorey-LislePYuanYBudget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancerJ Manag Care Pharm200915646747519610679
   PubMed Web of Science ®Google Scholar
• SparanoJAVrdoljakERixeORandomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol201028203256326320530276
   PubMed Web of Science ®Google Scholar
• ThomasESGomezHLLiRKIxabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatmentJ Clin Oncol200725335210521717968020
   PubMed Web of Science ®Google Scholar
• DufresneAPivotXTournigandCImpact of chemotherapy beyond the first line in patients with metastatic breast cancerBreast Cancer Res Treat2008107227527917380382
   PubMed Web of Science ®Google Scholar
• JordanMAKamathKMannaTThe primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growthMol Cancer Ther2005471086109516020666
   PubMed Web of Science ®Google Scholar
• JordanMAWalkerDde ArrudaMSuppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor actionBiochemistry1998375017571175789860873
   PubMed Web of Science ®Google Scholar
• MillerRKMatheosDRoseMDThe cortical localization of the microtubule orientation protein, Kar9p, is dependent upon actin and proteins required for polarizationJ Cell Biol1999144596397510085294
   PubMed Web of Science ®Google Scholar
• PasquierEKavallarisMMicrotubules: a dynamic target in cancer therapyIUBMB Life200860316517018380008
   PubMed Web of Science ®Google Scholar
• JordanMAKamathKHow do microtubule-targeted drugs work? An overviewCurr Cancer Drug Targets20077873074218220533
   PubMed Web of Science ®Google Scholar
• HigaGMThe microtubule as a breast cancer targetBreast Cancer201118210311920862571
   PubMed Web of Science ®Google Scholar
• KavallarisMAnnereauJPBarretJMPotential mechanisms of resistance to microtubule inhibitorsSemin Oncol2008353 Suppl 3S22S2718538175
   PubMed Web of Science ®Google Scholar
• SwainSMArezzoJCNeuropathy associated with microtubule inhibitors: diagnosis, incidence, and managementClin Adv Hematol Oncol20086645546718567992
   PubMedGoogle Scholar
• LeeJJSwainSMPeripheral neuropathy induced by microtubule-stabilizing agentsJ Clin Oncol200624101633164216575015
   PubMed Web of Science ®Google Scholar
• JimenoAEribulin: rediscovering tubulin as an anticancer targetClin Cancer Res200915123903390519509144
   PubMed Web of Science ®Google Scholar
• DabydeenDABurnettJCBaiRComparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulinMol Pharmacol20067061866187516940412
   PubMed Web of Science ®Google Scholar
• SmithJAWilsonJAzarenkoOEribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instabilityBiochemistry20104961331133720030375
   PubMed Web of Science ®Google Scholar
• OkounevaTAzarenkoOWilsonLInhibition of centromere dynamics by eribulin (E7389) during mitotic metaphaseMol Cancer Ther2008772003201118645010
   PubMed Web of Science ®Google Scholar
• HuyckTKGradisharWManuguidFKirkpatrickPEribulin mesylateNat rev Drug Discov201110317317421358731
   PubMed Web of Science ®Google Scholar
• TanARRubinEHWaltonDCPhase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumorsClin Cancer Res200915124213421919509146
   PubMed Web of Science ®Google Scholar
• ZhangZYKingBMPelletierRDWongYNDelineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4Cancer Chemother Pharmacol200862470771618431572
   PubMed Web of Science ®Google Scholar
• HamelENatural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin BPharmacol Ther199255131511287674
   PubMed Web of Science ®Google Scholar
• TowleMJSalvatoKABudrowJIn vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin BCancer Res20016131013102111221827
   PubMed Web of Science ®Google Scholar
• NewmanSEribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancerCurr Opin Investig Drugs200781210571066
   Google Scholar
• MinamiHMNagaiSMukaiHNamikiMA phase I study of eribulin mesylate (E7389) in patients with refractory cancersEur J Cancer2008Suppl 6140 abstract 446
   Web of Science ®Google Scholar
• GoelSMitaACMitaMA phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignanciesClin Cancer Res200915124207421219509177
   PubMed Web of Science ®Google Scholar
• SynoldTWMorganRJNewmanEMA phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer consortium trialJ Clin Oncol20052316S3036
   Web of Science ®Google Scholar
• SwamiUPetrylakDPRaftopoulosHPhase IB study of eribuin mesylate in combination with carboplatin inpatients with advanced solid tumorsJ Clin Oncol20102815s
   PubMed Web of Science ®Google Scholar
• CortesJVahdatLBlumJLPhase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabineJ Clin Oncol201028253922392820679609
   PubMed Web of Science ®Google Scholar
• IwataHAogiKMasudaNEfficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancerJ Clin Oncol201028151081
   Web of Science ®Google Scholar
• VahdatLTPruittBFabianCJPhase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol200927182954296119349550
   PubMed Web of Science ®Google Scholar
• CortesJO’ShaughnessyJLoeschDEribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyLancet2011377976991492321376385
   PubMed Web of Science ®Google Scholar
• TwelvesCLoeschDBlumJLA phase III study (EMBRACE) of eribulin mesylate versus treatment of physicians’ choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol20102818s
   Web of Science ®Google Scholar
• TwelvesCCortesJVahdatLTPhase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancerClin Breast Cancer201010216016320299316
   PubMed Web of Science ®Google Scholar
• MorrisPGMcArthurHLHudisCATherapeutic options for metastatic breast cancerExpert Opin Pharmacother200910696798119351274
   PubMed Web of Science ®Google Scholar
• MurphyCGFornierMHER2-positive breast cancer: beyond trastuzumabOncology (Williston Park)201024541041520480738
   PubMed Web of Science ®Google Scholar
• Study Comparig Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer. NCT00879086 Available from: http://clinicaltrials.gov/ct2/show/NCT00879086Accessed October 11, 2010
   Google Scholar